Signal brief

The company's reported Q3 miss and lowered FY25 revenue outlook are fundamentally negative catalysts that typically drive selling pressure in small-cap healthcare stocks. The market reaction — roughly 60% decline over the past month and a recent 23.8% one-day drop to $4.17 — shows investor confidence has deteriorated. Although management frames the weakness as timing-related and highlights margin and debt initiatives, guidance reductions directly compress near-term revenue and cash-flow expectations, increasing downside risk. Comparable peers in the article (e.g., Neuronetics/STIM) who cut guidance experienced significant share-price declines, demonstrating a well-established pattern: guidance misses in niche healthcare companies often produce outsized negative moves and extended underperformance until credible execution or upside revisions occur. The RSI near 30 signals oversold conditions that can produce short-term mean-reversion bounces, but does not negate the negative signal from the guidance cut and deteriorating price action.